Empiric Carbapenems for Nosocomial Pneumonia: Is Hindsight Clearer in 2020?

Nathaniel J. Rhodes; Richard G. Wunderink

doi:10.1016/j.chest.2020.11.003

Empiric Carbapenems for Nosocomial Pneumonia: Is Hindsight Clearer in 2020?

Nathaniel J. Rhodes^*, Richard G. Wunderink

^*Corresponding author for this work

Medicine, Pulmonary Division

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	897-899
Number of pages	3
Journal	CHEST
Volume	159
Issue number	3
DOIs	https://doi.org/10.1016/j.chest.2020.11.003
State	Published - Mar 2021

Funding

FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: N. J. R. discloses receipt of research funds from the American Association of Colleges of Pharmacy, Hartford Hospital and Paratek; receipt of honoraria from the American Society of Health Systems Pharmacists; and patent: WO2017161296A1 (ANTIBIOTIC-COATED NANOPARTICLES). R. G. W. discloses he has received consulting fees from Merck, Shionogi, Microbiotix and bioMerieux, and is on data safety monitoring boards for Pfizer and Vir.

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.chest.2020.11.003

Cite this

@article{1d471470a8f0436180b6beadb59f85a8,

title = "Empiric Carbapenems for Nosocomial Pneumonia: Is Hindsight Clearer in 2020?",

author = "Rhodes, {Nathaniel J.} and Wunderink, {Richard G.}",

note = "Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: N. J. R. discloses receipt of research funds from the American Association of Colleges of Pharmacy, Hartford Hospital and Paratek; receipt of honoraria from the American Society of Health Systems Pharmacists; and patent: WO2017161296A1 (ANTIBIOTIC-COATED NANOPARTICLES). R. G. W. discloses he has received consulting fees from Merck, Shionogi, Microbiotix and bioMerieux, and is on data safety monitoring boards for Pfizer and Vir.",

year = "2021",

month = mar,

doi = "10.1016/j.chest.2020.11.003",

language = "English (US)",

volume = "159",

pages = "897--899",

journal = "CHEST",

issn = "0012-3692",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Empiric Carbapenems for Nosocomial Pneumonia

T2 - Is Hindsight Clearer in 2020?

AU - Rhodes, Nathaniel J.

AU - Wunderink, Richard G.

N1 - Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: N. J. R. discloses receipt of research funds from the American Association of Colleges of Pharmacy, Hartford Hospital and Paratek; receipt of honoraria from the American Society of Health Systems Pharmacists; and patent: WO2017161296A1 (ANTIBIOTIC-COATED NANOPARTICLES). R. G. W. discloses he has received consulting fees from Merck, Shionogi, Microbiotix and bioMerieux, and is on data safety monitoring boards for Pfizer and Vir.

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85101193054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101193054&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2020.11.003

DO - 10.1016/j.chest.2020.11.003

M3 - Editorial

C2 - 33678269

AN - SCOPUS:85101193054

SN - 0012-3692

VL - 159

SP - 897

EP - 899

JO - CHEST

JF - CHEST

IS - 3

ER -

Empiric Carbapenems for Nosocomial Pneumonia: Is Hindsight Clearer in 2020?

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this